Tang C, Liu Y, Qin H, Li X, Guo W, Li J, Wang W, Qu L, Hu H, Xu C, Zheng L, Huang Y, Liu B, Gao H, Halleen JM, Liu X 2013 Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta 426:102-107.

Ylipahkala H, Fagerlund KM, Janckila AJ, Houston B, Laurie D, Halleen JM 2009 Specificity and clinical performance of two commercial TRACP 5b immunoassays. Clin Lab 55:223-238.

Fagerlund KM, Janckila AJ, Ylipahkala H, Tiitinen SL, Nenonen A, Cheng S, Uusi-Rasi K, Yam LT, Väänänen HK, Halleen JM 2008 Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment. Clin Lab 54:347-354.

Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK 2006 Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 52:499-509.

Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Väänänen HK, Suominen P, Helenius H, Salminen E 2006 Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 26:3127-3132.

Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, Väänänen HK 2005 Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol 44:742-747.

Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen HK, Halleen JM 2005 Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover. J Bone Miner Res 20:1804-1812.

Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Åkesson K, Obrant KJ 2004 Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386-393.

Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM 2004 Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883-890.

Uusi-Rasi K, Kannus P, Cheng S, Sievanen H, Pasanen M, Heinonen A, Nenonen A, Halleen J, Fuerst T, Genant H, Vuori I 2003 Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone 33:132-143.

Cheng S, Tylavsky F, Kroger H, Karkkainen M, Lyytikainen A, Koistinen A, Mahonen A, Alen M, Halleen J, Vaananen K, Lamberg-Allardt C 2003 Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls. Am J Clin Nutr 78(3):485-492.

Cheng S, Sievanen H, Heinonen A, Uusi-Rasi K, Carbone L, Tylavsky F, Halleen J, Kannus P 2003 Does hysterectomy with ovarian conservation affect bone metabolism and density? J Bone Miner Metab 21:12-16.

Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, Cheng S, Väänänen HK 2002 Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71:20-25.

Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT 2002 Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 320:49-58.

Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK 2001 Serum Tartrate-resistant Acid Phosphatase 5b is a Specific and Sensitive Marker of Bone Resorption. Clin Chem 47:597-600.

Halleen JM, Ranta R 2001 Tartrate-resistant Acid Phosphatase as a Serum Marker of Bone Resorption. Am Clin Lab 20:29-30 (invited review article).

Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK 2000 Tartrate-Resistant Acid Phosphatase 5b, a Novel Serum Marker of Bone Resorption. J Bone Miner Res 15:1337-1345.

Halleen JM, Karp M, Viloma S, Laaksonen P, Hellman J, Käkönen SM, Stepan JJ, Holmes SD, Väänänen HK, Pettersson K 1999 Two-Site Immunoassays for Osteoclastic Tartrate-Resistant Acid Phosphatase Based on Characterization of Six Monoclonal Antibodies. J Bone Miner Res 14:464-469.

Nakasato YR, Janckila AJ, Halleen JM, Väänänen HK, Walton SP, Yam LT 1999 Clinical significance of immunoassays for type 5 tartrate-resistant acid phosphatase. Clin Chem 45:2150-2157.

Halleen JM, Hentunen TA, Karp M, Käkönen SM, Pettersson K, Väänänen HK 1998 A Direct Two-Site Immunoassay for Tartrate-Resistant Acid Phosphatase. J Bone Miner Res 13:683-687

Halleen J, Hentunen TA, Hellman J, Väänänen HK 1996 Tartrate-Resistant Acid Phosphatase: Purification and Development of an Immunoassay. J Bone Miner Res 11:1444-1452.

OncoBone

AT YOUR SERVICE

If you are interested to learn more,
see our services or contact us directly.

    Scientist.com logo Science Exchange logo

    Copyright © 2021 OncoBone Ltd